Dear Carl,
You were right all along. ImClone was worth a lot more than people thought. How about $60 a share, and we’ll call it a deal? Let’s talk.
Sincerely,
Jim
Bristol-Myers Squibb offered to buy ImClone Systems, maker of cancer drug Erbitux, for $60 a share, or about $4.5 billion this morning. The companies, which jointly market the [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment